Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab

被引:0
|
作者
Carlo Putzu
Diego Luigi Cortinovis
Francesca Colonese
Stefania Canova
Ciriaco Carru
Angelo Zinellu
Panagiotis Paliogiannis
机构
[1] University Hospital of Sassari (AOU),Medical Oncology Unit
[2] San Gerardo Hospital,Medical Oncology Unit
[3] University of Sassari,Department of Biomedical Sciences
来源
关键词
Lung cancer; Nivolumab; Immunotherapy; Blood cell counts; NLR;
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer. Nivolumab, a monoclonal antibody that targets programmed death-1 (PD-1), was the first immune checkpoint inhibitor approved for the treatment of patients with advanced/metastatic NSCLC not responding to platinum-based chemotherapy. Biomarkers predicting response to these therapies would allow early identification of non-responders and timely implementation of appropriate combination strategies, avoiding inadequate and expensive therapies. The role of the neutrophil to lymphocyte ratio and other blood cell count indexes as possible biomarkers of response has been recently investigated. We discuss the encouraging results reported on the topic, provide new data from our personal experience, and discuss opportunities for further research.
引用
收藏
页码:1349 / 1353
页数:4
相关论文
共 50 条
  • [31] Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab
    Curioni-Fontecedro, A.
    Ickenberg, C.
    Franzen, D.
    Rogler, G.
    Burger, I. A.
    van den Broek, M.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 2040 - 2041
  • [32] Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
    Katsura, Hideyuki
    Suga, Yukio
    Araya, Tomoyuki
    Kita, Toshiyuki
    Yoneda, Taro
    Tanaka, Nobuyoshi
    Kawabata, Ayumi
    Ishita, Sotoki
    Mase, Hiroki
    JOURNAL OF CANCER, 2019, 10 (10): : 2139 - 2144
  • [33] Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab
    Turgeman, Ilit
    Wollner, Mira
    Hassoun, Gamal
    Bonstein, Lilach
    Bar-Sela, Gil
    ANTI-CANCER DRUGS, 2017, 28 (07) : 811 - 814
  • [34] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [35] Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab
    Tabchi, Samer
    Weng, Xiaoduan
    Blais, Normand
    LUNG CANCER, 2016, 99 : 123 - 126
  • [36] Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer
    Rossi, Sabrina
    Toschi, Luca
    Finocchiaro, Giovanna
    Santoro, Armando
    IMMUNOTHERAPY, 2020, 12 (10) : 715 - 724
  • [37] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [38] Effect and biomarker of Nivolumab for non-small-cell lung cancer
    Wang, Li
    Zhao, Deze
    Qin, Kang
    Ul Rehman, Faisal
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [39] Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer
    Verma, Saurav
    Vincent, Mark
    Breadner, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (16): : 1534 - 1534
  • [40] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302